Previous 10 | Next 10 |
12-Month Topline Results from Phase 2b ASTEROID Study with Setrusumab for Osteogenesis Imperfecta (OI) Expected in Q4 2019; Positive 6-Month Data to be Featured in Late-Breaking Oral Presentation at ASBMR 2019 Conference Call Today at 8:30 a.m. EDT / 1:30 p.m. BST LONDON and REDWOOD C...
Noteworthy events during the week of September 15 - 21 for healthcare investors. More news on: CRISPR Therapeutics AG, Pluristem Therapeutics Inc., GlaxoSmithKline plc, Healthcare stocks news, , Read more ...
LONDON and REDWOOD CITY, Calif., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or the “Company” or the “Group,” a clinical stage biopharmaceutical company focused on rare diseases, today announces tha...
Gainers: OpGen (NASDAQ: OPGN ) +79% . Marinus Pharmaceuticals (NASDAQ: MRNS ) +35% . Top Ships (NASDAQ: TOPS ) +25% . Natuzzi S.p.A. (NYSE: NTZ ) +23% . Mereo BioPharma Group (NASDAQ: MREO ) +23% . Ovid Therapeutics (NASDAQ: OVID ) +19% . Owens & Minor (NYSE: OMI ) +19% . ...
Thinly traded nano cap Mereo BioPharma Group plc ( MREO +20.3% ) is up on average volume, a scant 21K shares, in response to its announcement that six-month interim data form the open-label arm of its Phase 2b clinical trial, ASTEROID , evaluating setrusumab (BPS-804) in patients with o...
LONDON and REDWOOD CITY, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or the “Company” or the “Group,” a clinical stage biopharmaceutical company focused on rare diseases, today announce...
LONDON and REDWOOD CITY, Calif., July 16, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), a clinical stage biopharmaceutical company focused on rare diseases, today announces the appointment of Richard Francis as Head of Pharmaceutical Development, effective Aug...
Gainers: Capricor Therapeutics (NASDAQ: CAPR ) +148% . Carolina Trust BancShares (NASDAQ: CART ) +30% . SSLJ.com Limited (YGTY) +29% . Chicken Soup for the Soul Entertainment (NASDAQ: CSSE ) +22% . AVROBIO (NASDAQ: AVRO ) +22% . Mereo BioPharma Group (NASDAQ: MREO ) +21% . Amer...
Thinly traded nano cap Mereo BioPharma Group plc ( MREO +31.1% ) is up on almost a 13x surge in volume, albeit on turnover of only 261K shares, in response to its announcement that the FDA is on board with a potential accelerated approval pathway for bispecific antibody navicixizumab for...
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN LONDON and REDWOOD CITY, Calif., July 15, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma...
News, Short Squeeze, Breakout and More Instantly...
Mereo BioPharma Group Company Name:
MREO Stock Symbol:
NASDAQ Market:
LONDON, April 03, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutica...
LONDON, April 03, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate ...
2024-03-28 08:00:08 ET Gil Blum from Needham issued a price target of $6.00 for MREO on 2024-03-28 07:08:00. The adjusted price target was set to $6.00. At the time of the announcement, MREO was trading at $3. The overall price target consensus is at $4.00 with high pric...